Pharma Has Funded Hilary to Tune of Nearly $1 Million This Cycle, But Supports Republicans Overall
According to the latest data from the Federal Election Commission released on Monday, September 12, 2016 (here), Hilary Clinton has received more than $990,000 in funds from the healthcare/pharma industry although the industry has donated nearly 50% more money to Republican presidential candidates than to Democratic candidates.Apparently, Trump doesn't need no stinkin' money from pharma, which only gave him about $95K. Does that mean that Trump will come out swinging harder at pharma during tonight's presidential debate than will Clinton?Read more » (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - September 26, 2016 Category: Pharmaceuticals Tags: Donald Trump Hilary Clinton Lobbying Politics Source Type: blogs
How to Develop a Nose for Innovation
Philip Blake, President& CEO, Bayer is giving an advice on how to develop a nose for innovation and talks specific experiences he has had that helped him on this journey.You will find a number of people who ’ve been in the industry, have lived in some ways through the golden age - the age where there’s been a willingness to pay and be able to clearly demonstrate the value the innovation machines delivered over the last few decades.I had the good fortune to start out as a sales repThat amazing time when you go from being in research, and you ’re not really sure where the next grant is coming from, and suddenly, a ...
Source: ePharma Summit - September 22, 2016 Category: Pharmaceuticals Tags: biotech innovation commercial ePharma Healthcare innovate pharma strategy pharmaceutical strategy science Source Type: blogs
[FREE WEBINAR]: Learn about Web and Business Solutions with Jamie Beckland
Jamie Beckland has been delivering custom web solutions for more than 10 years, and built his first social media community in 2004. Prior to Janrain, Jamie led the emerging media practice at White Horse, and has worked as a marketer and technologist with clients including Coca-Cola, Financial Times, Samsung, Wells Fargo, L ’Occitane, The Brooking Institution, and many others. He frequently speaks about technology trends and writes for Mashable, Social Media Examiner, iMediaConnection, AdAge, and other publications.Want to know what you'll learn from this insightful webinar? Here's a bit of context.You'll learn how to:Acq...
Source: ePharma Summit - September 20, 2016 Category: Pharmaceuticals Tags: business solutions client relations community building digital marketing digital publishing ePharma Janrain media relations technologist web analytics web solutions Source Type: blogs
[Infographic] These Innovative Tools Can Reduce R & D Costs
High costs and long time horizons put immense pressure on the drug development industry to find ways to get drugs to the market faster while reducing cost and time. The opportunity to use special regulatory designations (i.e., “breakthrough drug”) offer the advantage of expedited review to certain types of drugs. However, it’s the embracement of novel technological tools that can truly impact the speed of R&D. Download thisSDG infographicfor an overview of the many new and innovative tools that can reduce development costs, build and streamline pipelines, and shorten time to regulatory approval. Source:SDG (...
Source: ePharma Summit - September 15, 2016 Category: Pharmaceuticals Tags: #PSANYC16 biotech innovation drug patents drugs drugs regulation ePharma FDA generic drugs health costs medical technology & research and development Source Type: blogs
Deborah Waterhouse Speaks Patient Care and the Growth of Digital Medicine
Deborah Waterhouse, the SVP of GlaxoSmithKline (GSK)'s Business Unit, has spent over two decades working across many cultures, with the pharmaceutical industries, with a track record of developing clear strategies, strong alignment and excellent execution to drive shareholder and customer value. She is not only passionate about working in healthcare, but is motivated every day by the opportunity to serve customers and make a difference to patients.Thankfully, we had the opportunity of speaking with Waterhouse, who'll also be a keynote at our annual Pharmaceutical Strategy Conference (PSA), to share her expert opinion on&nb...
Source: ePharma Summit - September 12, 2016 Category: Pharmaceuticals Tags: Digital pharma disease management health system Healthcare technology patient care Pharmaceutical Industry pharmaceutical strategy Pharmaceutical Strategy Conference primary care PSA Source Type: blogs
PSA 2015 Snapshot: Pharma Experts Discuss Market Access for Breakthrough Medicines, What's Next?
In 2015, our annual Pharmaceutical Strategy Conference (PSA) hosted four pharmaceutical experts during our panel discussing market access and new payment methods for breakthrough medicines.Our panelists included:Garrett Ingram, VP, Head of US Market Access, SanofiSam Rasty, PhD, VP& Head of New Products, Rare Diseases Business Unit, Shire Pharmaceuticals in Lexington, Mass. Rod Cavin, Managing Director, Health Strategies Group. The company provides market access, insight and the market access research in the US and the U5 for pharmaceutical and device companies. Roger Longman, Chief Executive Officer, Real En...
Source: ePharma Summit - September 7, 2016 Category: Pharmaceuticals Tags: drug pricing drugs medication Pharma pharma marketing pharmaceutical strategy pharmaceutical stratey conference PSA Source Type: blogs
FDA Readies Itself for Direct-to-Consumer Off-Label Drug Promotion
In what's been described as a"surprise move" (here) the FDA recently published a notice that it will hold a 2-day public hearing this November to obtain"input on issues" related to off-label product communications about by pharmaceutical and medical device companies. FDA defines off label use of drugs as,"Use for indication, dosage form, dose regimen, population or other use parameter not mentioned in the approved labeling."FDA's authority to prevent or even regulate off-label promotion by pharmaceutical companies is dwindling. After losing to Amarin in court ("FDA Deal with Amari...
Source: Pharma Marketing Blog - September 3, 2016 Category: Pharmaceuticals Tags: DTC Advertising FDA guidelines off-label promotion regulations Washington Legal Foundation Source Type: blogs
FDA May Have No Choice But to Allow Direct-to-Consumer Off-Label Drug Promotion
In what's been described as a"surprise move" (here) the FDA recently published a notice that it will hold a 2-day public hearing this November to obtain"input on issues" related to off-label product communications about by pharmaceutical and medical device companies. FDA defines off label use of drugs as,"Use for indication, dosage form, dose regimen, population or other use parameter not mentioned in the approved labeling."FDA's authority to prevent or even regulate off-label promotion by pharmaceutical companies is dwindling. After losing to Amarin in court ("FDA Deal with Amari...
Source: Pharma Marketing Blog - September 3, 2016 Category: Pharmaceuticals Tags: DTC Advertising FDA guidelines off-label promotion regulations Washington Legal Foundation Source Type: blogs
Are We at the Saturation Point Viz-a-Viz Celebrity Pharma Endorsements?
I read with interest today's email missive from Bob Ehrlich, Chairman of DTC Perspectives. He was talking about the"Dry Eye DTC Battle" between Allergan's Restasis and the new kid on the bloc: Shire's Xiidra (two i's - get it? aka two"eyes").Ehrlich pointed out that Shire enlisting Jennifer Aniston is a"big get. Getting a movie star to promote the dry eye condition must have cost Shire a lot in talent fees," said Ehrlich."Obviously they think she is worth it. Her ad just went on air under the'myeyelove' title" (read"Jennifer Aniston is Shilling for Shire!...
Source: Pharma Marketing Blog - September 2, 2016 Category: Pharmaceuticals Tags: Allergan Celebrity Endorsement Dry Eyes Shire Source Type: blogs
Two Pieces of Advice to Pharma on How to Price Drugs By Everett Neville
The biopharmaceutical sector has faced difficulties in recent years, as large and small companies are facing growing criticism over the prices of branded pharmaceuticals.When asked about rising drug prices, Everett Neville, Vice President and the Chief Trade Relations Officer of Express Scripts gives two pieces of advice to Pharma on how to price their drugs.First of all, what is the value of the drug? The problem with this is, we are never going to agree. In the recent years manufacturers have put a really good faith in attempt to figure out the value of their drugs, but the industry has got to come to some understandings...
Source: ePharma Summit - September 1, 2016 Category: Pharmaceuticals Tags: Big Pharma drug prices drug pricing drugs Healthcare healthcare cost medication pharma strategy PSA treatment Source Type: blogs
Branded as Well As Unbranded Vaccine Ads Are the Scariest!
WhenSTATnews reporter Rebecca Robbins (@rebeccadrobbins) interviewed me about what's behind ominous unbranded"disease awareness" ads, I opined that if you ’re a drug maker, “you don’t want to attach a dark image to the brand — so you’re attaching this dark imagery to a medical condition instead,” which leaves room for a branded ad that shows “the bright side: that there’s this product that can save the day” (Read"#Pharma'Disease Awareness' Ads: Are They'Stealthy' Fear Mongering Set Pieces?").That"conventional wisdom" or"rule" -- if it is one -- o...
Source: Pharma Marketing Blog - August 31, 2016 Category: Pharmaceuticals Tags: Gardasil GSK HPV Meningitis B Pfizer Trumenba Vaccine Source Type: blogs
Do Efforts to Expand Digitally in Healthcare Compromise Patients' Confidentiality?
Over the past few decades, the world has seen a dramatic rise in the use of technology. With these changes, sharing of information has also changed as, individuals are more likely to share and seek information through social media avenues, apps, or wearable devices. Though the business world was quick to adapt to these changes, the healthcare industry is just beginning to integrate technology into day-to-day tasks. Healthcare providers have had to make big changes to allow for this transition.As the interest in digital health grows, many experts have started to ask whether patient confidentiality is at risk. For example, i...
Source: ePharma Summit - August 25, 2016 Category: Pharmaceuticals Tags: Digital Health Digital health records Digital pharma ehrs Electonic Health Records ePharma Medical records mhealth patient confidentiality patient records pharma strategy Source Type: blogs
Effective Primary Care Can Enhance Disease Prevention
Research has demonstrated the important role of effective primary care in illness prevention and earlier – and less costly – disease interventions. This certainly applies to chronic conditions like hypertension, diabetes, and mental illness, which drive more than 85% of healthcare cost. Though in the US there are currently proportionally fewer primary care physicians than other industrialized nations, and patients visit their primary care physician less frequently than in other countries, primary care must play a key role in the successful expansion of healthcare coverage. ...
Source: ePharma Summit - August 24, 2016 Category: Pharmaceuticals Tags: #PSANYC16 chronic illness disease interventions illness prevention Pharma pharma strategy Preventative healthcare primary care Primary care doctors primary care physician PSA conference Source Type: blogs
The Addyi Report Card: Crooked Valeant Fools FDA Again
Click on image for enlarged view or get PDFhere."Fool me once, shame on you; fool me twice, shame on me," should be FDA's response to a report card released by the National Women ’s Health Network advocacy group and shown here.FDA was first"fooled" into approving Addyi based on a dicey self-assessment questionnaire, which formed the basis for the drug's efficacy in clinical trials (read"The #Pharma-Developed Self-Assessment Questionnaire that Got Addyi Approved") and by"patient advocate" testimony (read"The Power of Patient Input: How FDA Learned to Love& Approve A...
Source: Pharma Marketing Blog - August 19, 2016 Category: Pharmaceuticals Tags: Addyi FDA REM Sprout Valeant Source Type: blogs
New Technologies that Are Transforming the World of Healthcare
There is one thing that is certain about modern civilization, technology is always advancing and evolving. This is certainly true of the medical world. Millions of dollars are put into medical research every year. Much of that research is bearing fruit in the form of new and exciting medical technology.As medical tech improves, so will the lives of people. With this in mind, here is a look at some new medical technologies that are taking the world by storm.3D Printing One technology that has certainly made an impact recently is 3D printing.According to statistics, it's predicted that the 3D printing industry will grow...
Source: ePharma Summit - August 16, 2016 Category: Pharmaceuticals Tags: 3d printing digital healthcare Digital pharma digital solution Health tech medical imaging medical technology Source Type: blogs
